Abstract Number: 2331 • ACR Convergence 2025
Coping with Rheumatic Stressors in Axial Spondyloarthritis: Association with Patient Characteristics and Disease Phenotypes and Changes Over Time
Background/Purpose: To identify patient characteristics and disease phenotypes associated with coping strategies in axial spondyloarthritis (axSpA), and assess whether coping strategies change over time.Methods: Data…Abstract Number: 1454 • ACR Convergence 2025
Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. Previous analyses of phase (Ph)2b/3 safety data (data…Abstract Number: 1410 • ACR Convergence 2025
Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort
Background/Purpose: In axial spondyloarthritis cohorts, patient reported outcomes are vital for tracking disease progression and response to therapy. However, many cohorts enrolled prior to the…Abstract Number: 0547 • ACR Convergence 2025
Determinants of Difficult-to-Manage Axial Spondyloarthritis: Results from a Prospective Cohort Study
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) group has recently introduced a consensus-based definition for difficult-to-manage (D2M) axial spondyloarthritis (axSpA) to identify patients with…Abstract Number: 2636 • ACR Convergence 2025
Autoantibodies to 14-3-3 eta: A Novel Diagnostic Biomarker for Axial Spondyloarthritis
Background/Purpose: People with axial spondyloarthritis (axSpA), typically present with persistent back pain and experience up to a 10-year diagnostic delay that may lead to irreversible…Abstract Number: 2326 • ACR Convergence 2025
Impact of Regular Exercise, Mobility Impairment, and Obesity on Quality of Life in Patients with Axial Spondyloarthritis: A Cross-Sectional Analysis from the Brazilian Registry of Spondyloarthritis
Background/Purpose: Axial Spondyloarthritis (axSpA) is a chronic inflammatory disease that impairs quality of life. While pharmacological treatment is central to axSpA management, non-pharmacological strategies are…Abstract Number: 1452 • ACR Convergence 2025
Clinical and Demographic Characteristics of Treatment-Refractory Axial Spondyloarthritis: Data from the Greek AxSpA Registry
Background/Purpose: Axial spondyloarthritis (AxSpA) is a chronic inflammatory disease that significantly impairs quality of life. Although biologic and targeted synthetic DMARDs (b/tsDMARDs) have improved disease…Abstract Number: 1408 • ACR Convergence 2025
When Damage and Disability Diverge: Unraveling Sex-Based Drivers of Axial Spondyloarthritis Burden
Background/Purpose: Sex differences in axial spondyloarthritis (axSpA) are well recognized, but their clinical consequences remain understudied in real-world settings. This study aimed to assess sex-based…Abstract Number: 0546 • ACR Convergence 2025
Multimorbidity clusters in psoriatic arthritis, psoriasis, and axial spondyloarthritis and their association with healthcare utilization: A population-based study
Background/Purpose: Multimorbidity (≥ 2 chronic conditions) is common in inflammatory diseases such as psoriatic arthritis (PsA), psoriasis (PsO), and axial spondyloarthritis (AxSpA), increasing patient burden…Abstract Number: 2634 • ACR Convergence 2025
Sex differences in medication discontinuation in axial spondyloarthritis
Background/Purpose: Women with axial spondyloarthritis (axSpA) tend to report worse outcomes and greater functional impairment than men. They may also respond less favorably to medication,…Abstract Number: 2322 • ACR Convergence 2025
Gender-related Differences in Peripheral and Axial Spondyloarthritis
Background/Purpose: This study sought to compare clinical characteristics between female and male patients with spondyloarthritis (SpA) in a Turkish population.Methods: This study included 489 peripheral…Abstract Number: 1451 • ACR Convergence 2025
Bimekizumab was Efficacious Regardless of Age, BMI, CRP, or HLA-B27 Status: 1-Year Results from Two Phase 3 Studies
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL-17A, has shown efficacy to Week (Wk) 52 in patients…Abstract Number: 1407 • ACR Convergence 2025
Trends in Diagnostic Timing and Clinical Features of Axial Spondyloarthritis by Sex and Clinical Subtype: A Multicenter Cohort Over Seven Decades
Background/Purpose: Axial Spondyloarthritis (axSpA) frequently eludes early recognition, particularly before structural sacroiliitis becomes visible. We analyzed decade-specific diagnosis delay, clinical subtype distribution, and first-symptom profiles…Abstract Number: 0541 • ACR Convergence 2025
Inflammatory Back Pain Is Not Associated With HLA-B27 Positivity or CRP Levels in a Nationally Representative U.S. Population
Background/Purpose: Inflammatory back pain (IBP) is a hallmark symptom of axial spondyloarthritis (axSpA) and is frequently used as a clinical entry point for further evaluation,…Abstract Number: 0068 • ACR Convergence 2024
Enhanced Expression of GPR65 in Inflammatory Sites and Bone Formation Regions in Ankylosing Spondylitis: Evidence from ScRNA-seq Analysis
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the axial skeleton. T helper 17 (Th17) cells play a pivotal role in the…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 67
- Next Page »
